Cancer research within the last decades elucidated signaling pathways and identified genes and proteins that lead or contribute to malignant transformation of a cell. Discovery of the Bcr-Abl oncoprotein as the molecular abnormality causing chronic myeloid leukemia (CML) paved the way for the development of a targeted anticancer therapy. The substantial activity of imatinib mesylate (STI571, Glivec) in CML and Philadelphia (Ph)-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) changed the therapeutic approach to Ph+ leukemia and rang the bell for a new era of anticancer treatment. However, when the phenomenon of relapse occurred despite continued imatinib treatment, we had to learn the lesson that imatinib can select for a resistant disease clone. If such a clone still depends on Bcr-Abl, it either carries a BCR-ABL point mutation that prevents binding of the drug or expresses the fusion protein at high levels. Alternatively, leukemia cells that harbor secondary genetic alterations resulting in Bcr-Abl-independent proliferation are selected for their growth advantage in the presence of imatinib. Point mutations in the BCR-ABL kinase domain prevent binding of imatinib but still allow binding of ATP, thus retaining Bcr-Abl kinase activity. Mutated BCR-ABL is frequently detected in cases of imatinib-resistant Ph+ leukemia and therefore represents the main challenge for the investigation of alternative strategies to either overcome resistance or to prevent the emergence of a resistant leukemic clone. Leukemia (2003) 17, 829-838. doi:10.1038/sj.leu.2402889 Keywords: imatinib; Gleevec; Glívec; ST1571; CML, Bcr-Abl; mutation
Bcr-Abl as target for therapeutic kinase inhibition
Protein tyrosine kinases are enzymes that transfer phosphate groups from ATP to substrate proteins, thereby governing cellular processes such as growth and differentiation. Tight regulation of tyrosine kinases is indispensable and, if not maintained, deregulated kinase activity can lead to transformation and initiation of malignancy. The Ph chromosome, first described as a shortened chromosome 22, 1 results from a reciprocal translocation between the long arms of chromosomes 9 and 22, 2 and is present in approximately 95% of chronic myeloid leukemia (CML) patients and up to 20% of adult acute lymphoblastic leukemia (ALL). 3, 4 The Ph translocation gives rise to the oncogenic Bcr-Abl fusion protein that is characterized by a constitutively active tyrosine kinase. Bcr-Abl is sufficient to cause CML in mice, 5 and its transforming capacity strictly depends on tyrosine kinase activity. 6 This makes Bcr-Abl an attractive target for therapeutic intervention in CML and Ph+ ALL.
The 2-phenylaminopyrimidine class of small-molecule kinase inhibitors was identified using a high throughput screen of compound libraries at Ciba-Geigy (now Novartis). 7 Imatinib mesylate, a derivative of the initial lead compound, was found to inhibit autophosphorylation of four kinases: the receptor tyrosine kinase platelet-derived growth factor receptor (PDGF-R) a and b, the receptor tyrosine kinase cKit and the protein tyrosine kinase Abl, including its close homolog Arg. [8] [9] [10] [11] [12] Imatinib has been demonstrated to specifically inhibit oncogenic fusion proteins including Bcr-Abl p210, 13 p185, 14 TEL (ETV6)-Abl, 15 and TEL-PDGF-Rb. 15 Moreover, the compound inhibits cKit harboring oncogenic mutations. 16 In addition, imatinib proved to be active in a murine model of BCR-ABLinduced leukemia. 17, 18 Imatinib is active in CML and Ph+ ALL Phase I clinical studies showed impressive activity of the drug especially in late chronic phase CML (patients who failed interferon-based therapy) with 98% of the patients achieving complete hematologic responses (CHR). 19 Also in blast crisis CML and relapsed or refractory Ph+ ALL, imatinib induced encouraging remissions. 20 Overall response rates (CHR or marrow response or return to chronic phase) were 21/38 patients (55%) in myeloid blast crisis CML including four patients (11%) with CHR and 14/20 patients (70%) in lymphoid blast crisis or Ph+ ALL with four patients (20%) achieving a CHR. 20 In accordance with the dose-response relation in chronic phase CML and comparison of pharmacokinetic with in vitro data, doses of 400 mg for chronic phase CML to 600 mg for advanced phase CML were recommended for subsequent protocols. 21 Phase II clinical studies in late chronic phase (interferonrefractory and interferon-intolerant), 22 accelerated phase, 23 and myeloid blast crisis CML 24 confirmed phase I data and established imatinib as an effective and well-tolerated therapy. In late chronic phase CML, imatinib induced a CHR in 95% of 454 patients. A major cytogenetic response (0-35% Ph+ cells in metaphase in bone marrow) was observed in 60%. 22 In myeloid blast crisis CML, the administration of imatinib at 400 or 600 mg once daily led to sustained hematologic responses that lasted at least 4 weeks in 31% out of 229 patients, including 8% with a CHR. 24 In patients with relapsed or refractory Ph+ ALL or lymphoid blast crisis CML, imatinib (400 or 600 mg once daily) induced sustained responses in 27% out of 48 patients with a CHR in 6% of Ph+ ALL cases, and in 2/8 patients with lymphoid blast crisis CML including one patient with a sustained CHR. 25 
Clinical resistance to imatinib
Whereas almost all chronic phase CML patients durably respond, remissions in CML blast crisis and Ph+ ALL are only of short duration. In the phase I study, virtually all patients (19/ 20) with lymphoid blast crisis CML and Ph+ ALL, and 31/38 (82%) patients with myeloid blast crisis CML relapsed within several months (median 58 days for lymphoid blast crisis and 84 days for myeloid blast crisis), despite continued therapy with imatinib. 20 In the phase II studies, estimated overall survival was 4.9/6.6 months in patients with Ph+ ALL/lymphoid blast crisis CML, 25 and 6.9 months in myeloid blast crisis CML, 24 with an estimated overall survival rate of 40% at 6 months in Ph+ ALL and 43% at 9 months in myeloid blast crisis CML, respectively. 24, 25 Mechanisms of resistance to imatinib at the molecular level
The high activity of imatinib in chronic phase CML is evidently because of absolute dependence of the malignant clone on Bcr-Abl and its selective inhibition by imatinib. In advanced phase CML or Ph+ ALL, the combination of a high number of proliferating tumor cells and genomic instability [26] [27] [28] may lead to a particular high chance that secondary genetic alterations occur. 29 Clones that have acquired a genetic alteration that confers resistance to imatinib are selected by the drug. Intense research over the past 2 years elucidated mechanisms of resistance towards imatinib at the molecular level. Figure 1 illustrates molecular mechanisms of resistance towards imatinib that became evident so far. When a resistant clone still depends on Bcr-Abl, the oncoprotein must be active in the presence of imatinib (see Figure 1) , either by an increase of Bcr-Abl protein (Figure 1b) or by mutation of sites that are critical for binding the drug (Figure 1c ). If those secondary hits do not affect BCR-ABL, and independently mediate oncogenicity, these secondary genetic alterations may predominate in 'driving' the malignant clone ( Figure 1d ) despite effective Bcr-Abl kinase inhibition by imatinib. In either case, clinical resistance to imatinib will be the consequence.
In vitro models of imatinib resistance 33 Resistance to imatinib in Bcr-Abl-transformed cell lines is incomplete, occurring at concentrations where the residual activity of overexpressed Bcr-Abl may be sufficient for cell survival. High amounts of Bcr-Abl may thus allow the cell to maintain a 'baseline' level of signaling sufficient for cell survival even in the presence of imatinib. 18 Interestingly, Bcr-Abl overexpression and amplification of BCR-ABL in resistant sublines of LAMA84-r were reversible after the withdrawal of imatinib, and LAMA84-r cells at the same time regained sensitivity to imatinib. 34 Three imatinib-resistant human cell lines (K562-r, LAMA84-r, and AR230-r) were examined for overexpression of the MDR-1 gene, coding for the P-glycoprotein (Pgp), which functions as a multidrug resistance-associated drug transporter in the plasma membrane. In comparison with its sensitive counterparts, only LAMA84-r overexpressed Pgp, and sensitivity to imatinib was partially restored when Pgp was inhibited with verapamil. 31 There was no evidence for BCR-ABL gene mutations in resistant sublines of LAMA84, Ba/F3.p210, K562, and AR230, [30] [31] [32] consistent with the hypothesis that BCR-ABL point mutations may emerge from pre-existing clones in vivo that are selected for resistance in the presence of imatinib. The generation and selection of mutant forms of BCR-ABL may require in vivo conditions and therefore may not occur in vitro in a cell line derived from a single leukemic clone. However, the acquisition of a resistant phenotype in a human myeloid blast crisis KBM5 cell line by continuous exposure to imatinib was associated with only a marginal increase in the number of BCR-ABL gene copies and the level of Bcr-Abl protein. 35 Over and above, a single BCR-ABL point mutation (T315I) was detected in a fraction of the BCR-ABL gene copies in each of the clonally derived KBM5-STI571 R1.0 sublines, but not in parental KBM5 cells, suggesting that the mutation arose during drug exposure in vitro. 35 However, it cannot be ruled out that BCR-ABL point mutations emerge from clones that pre-exist in vivo and are selected for resistance in the presence of imatinib in vivo or in vitro. Thus, T315I mutations in KBM5 cells may be detected not until the presence of imatinib allows selection of single mutated cells. On the other hand, resistant sublines of LAMA84, Ba/F3.p210, K562, and AR230 may as well contain mutated BCR-ABL that has not been detected because the mutation affects only a portion of BCR-ABL transcripts, as it is the case for KBM5 cells.
Molecular mechanisms of imatinib resistance detected in patients
In an attempt to clarify the mechanism of resistance in imatinibtreated patients, an analysis performed by Gorre et al 36 resolved several issues. In cases of relapsed blast crisis CML and Ph+ ALL, resistance was associated with active Bcr-Abl kinase despite continued imatinib treatment, indicating that the disease still was driven by Bcr-Abl. 36 Patient cells displayed an impaired sensitivity to imatinib ex vivo, demonstrating that resistance represented a cell-intrinsic phenomenon. In three out of 11 cases, amplification of the BCR-ABL gene was found. 36 In one of those patients, BCR-ABL amplification disappeared after imatinib was discontinued, 36 indicating that amplification indeed was a consequence of selection in the presence of imatinib and confirming in vitro observations in resistant cell lines. 31, 34 In addition, nine patients were analyzed for the presence of point mutations in BCR-ABL that might confer resistance by interfering with binding of imatinib at the kinase domain. Strikingly, a change of C to T at nucleotide 1091 leading to an exchange of a threonine at position 315 to isoleucine (T315I) was found in six out of nine cases. One patient had both, BCR-ABL amplification and mutation. A crystal structure analysis of the catalytic domain of Abl in complex to a variant form of imatinib predicted the presence of a threonine at position 315 to be a key requirement for binding imatinib. 37 An exchange to isoleucine at this position prevents the formation of a critical hydrogen bond and adds an extra hydrocarbon group in its side chain, thereby leading to a steric clash with the drug (see Figure 2) . 37 Confirming these considerations, Bcr-Abl T315I remained phosphorylated in vitro in the presence of imatinib at concentrations sufficient to inhibit autophosphorylation of wild-type Bcr-Abl. 36 Soon after T315I had been described, a number of additional point mutations in BCR-ABL were identified in cases of refractory or relapsed CML or Ph+ ALL (see Table 1 ). [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] Importantly, it became evident that hematopoietic cell lines transduced with different mutant forms of BCR-ABL indeed display resistance towards imatinib. 42 Interestingly, there were differences in the extent of in vitro resistance: some mutant forms of Bcr-Abl (Y253H, E255K, E255V, and T315I; see Table 1 
SPOTLIGHT
by far exceed concentrations measured in patients 49 treated with imatinib. 42, 43 In contrast, the BCR-ABL mutant H396P had IC50 values that were nearby concentrations measured in treated patients. 42, 43 This indicates that increasing the dosage of imatinib may be beneficial in some cases of imatinib resistance due to mutated BCR-ABL.
Although all mutants examined so far demonstrated to be kinase-active, a recent report added two important issues to the matter: the kinase activity and ATP affinity in relation to wildtype Abl. 50 In this study, T315I retained only 61% of its kinase activity, suggesting that a possibly pre-existing clone harboring T315I may confer a growth advantage over wild-type Bcr-Abl only in the presence of imatinib, and, vice versa, stopping imatinib may allow the wild-type clone to come up as the predominant clone again. Moreover, T315I displayed a two-fold increase in its ATP affinity relative to wild-type Abl. 50 This may contribute to resistance in this and other mutations affecting the ATP binding site.
Genomic instability of Ph+ cells has been demonstrated at the cytogenetic and nucleotide level [26] [27] [28] and can be regarded as a prerequisite for the formation of BCR-ABL gene amplification (Figure 1b), mutation (Figure 1c) , and additional genetic changes (Figure 1d ) that contribute to the evolution of leukemia. Clonal evolution was demonstrated in 19/36 patients with imatinib resistance, 48 indicating selection of a leukemic clone occurred that has acquired genetic alterations in addition to BCR-ABL. The nature and frequency of those genetic abnormalities remain to be elucidated. Also in murine models of Ph+ leukemia, clonal selection has been observed in imatinib resistance (see 'Imatinib resistance in murine models of Bcr-Abl-induced leukemia' section).
Frequency of point mutations in relapsed vs primary resistant patients
Initially, BCR-ABL gene mutations were reported predominantly in cases of relapsing blast crisis CML or Ph+ ALL. 36, 42, 44, 46, 51 The discrepant frequency of BCR-ABL gene mutations that was initially reported by different authors [38] [39] [40] may be explained in part by differences in the technology that has been used for detection. In addition, patient selection may have a major impact on the frequency reported by different authors. It is 
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obvious that mutations represent the major cause of resistance in relapsed patients who initially experienced a hematologic response receiving imatinib (see Table 2 ). 41, 42, 47, 48, 51 Relapsed patients who have been reported so far mainly suffered from advanced phase CML and Ph+ ALL. In contrast, in hematologic 45, 48 or cytogenetic 41, 45, 47 nonresponders, mutations in BCR-ABL have been detected less frequently, indicating that other mechanisms, such as amplification of the BCR-ABL gene, 36, 48 or additional genetic alterations 48 may be important there. Those reports predominantly contained chronic and accelerated phase CML patients.
Taken together, BCR-ABL mutations seem to occur frequently in relapsing CML and Ph+ ALL after an initial response to imatinib, whereas in primary resistance, other mechanisms may predominate.
Important lessons learned from crystal structure and computer modeling
Three years ago, Schindler et al 37 examined the structural mechanism for inhibition of the Abl kinase by imatinib. A crystal structure analysis of the murine Abl kinase domain in complex with a variant of imatinib 37 and two recent publications reporting the crystal structure of imatinib in complex with the kinase domain of human Abl 52, 53 clarified that this drug achieves high specificity by recognizing the kinase domain of Abl when the activation loop (residues 381-402) adopts a closed, inactive conformation. In this conformation, the binding site of the substrate tyrosine is occupied by the region surrounding Y393, the major autophosphorylation site of Abl, and Y393 is not phosphorylated (see Figure 3) . Imatinib, exclusively binding to the closed, inactive conformation, might therefore be regarded as an inhibitor of Abl kinase activation. 52, 53 Moreover, a number of residues within the ATP binding site were predicted to be crucial for specific binding due to direct interaction with the inhibitor. Sequence comparison of Proposed mechanism for impaired binding of imatinib to H396P/R. The activation loop of c-Abl in the closed, inactive conformation and the catalytic site of the kinase are shown. Imatinib (green) can only bind to this closed conformation. In this condition, the activation loop (residues 381-402) is folded into the active site of the kinase, mimicking bound substrate. Y393, the major autophosphorylation site in Abl, is not phosphorylated, and is presented by a b-sheet (blue) to point into the active site, forming a hydrogen bond with D363 and R367. This b-sheet, a part of the activation loop, contains H396 (red). An exchange of this histidine to proline or arginine may lead to an extended conformation of the activation loop, thereby impairing the binding of imatinib. Generated with PDB 1IEP available from http://www.rcsb.org/pdb/.
Resistance of Philadelphia-chromosome positive leukemia N von Bubnoff et al 833 Leukemia SPOTLIGHT the inhibitor binding region of different protein kinases revealed two positions (T315 and A380) with bulkier side chains in imatinib-insensitive, compared to imatinib-sensitive, kinases. 54 Thus, a complex mechanism of interaction seems to be the key for the selectivity of this compound.
Strikingly, the results of crystallographic and computational studies perfectly matched the results of mutational analysis performed from patients: some of the residues, which have been identified to be critical, were actually found to be mutated in resistant patients. And, moreover, it is possible now to explain the insensitivity of mutated BCR-ABL at the molecular level. It is evident that BCR-ABL point mutants detected in patients with imatinib resistance can be divided into different categories: some are located at residues that are in direct contact with imatinib (see Figure 2) . Mutations affecting such positions (eg T315, F317, and F359, see Table 1 , Figure 2 ) may lead to a steric clash with the drug. The remaining mutations affect regions that have to adopt a specific conformation in order to allow binding of imatinib. Mutations at positions G250, Q252, and E255 are thought to destabilize the nucleotide-binding loop (P loop) that forms a part of the hydrophobic binding pocket for the drug (see Table 1 , Figure 2 ). Y253 stabilizes a region that forms a part of the binding pocket via a hydrogen bond with an asparagine at position 322 (see Table 1 ). Furthermore, Y272F in c-Abl, corresponding to Y253F in Bcr-Abl, activates transformation by c-Abl, 55 and was the first residue in the c-Abl catalytic domain demonstrated to induce resistance to imatinib. 56 There is evidence that Y272F in c-Abl and Y253F in Bcr-Abl confer a gain of function by interference with the binding of a putative cellular protein inhibitor, leading to an increase of catalytic activity in vivo, but not in vitro. 46, 50, 55 Positions V379, L387, and H396 are located within the activation loop. Their mutation is assumed to destabilize the autoinhibitory conformation of the activation loop, which is required for imatinib to bind (Table 1, Figure 2 ).
Role of a1 acid glycoprotein
At clinically relevant concentrations, imatinib is thought to be bound to plasma proteins, such as albumin and a1 acid glycoprotein (AGP). 57 When the amount of drug that is available within the cell is diminished because of extrinsic or host factors such as AGP plasma levels, selection of a clone that is partially resistant to imatinib because of mutation or amplification of BCR-ABL may be possible when the intracellular inhibitor concentration drops below values necessary for inhibition of that particular clone. Indeed, it has been proposed that increased levels of AGP might reduce the amount of unbound imatinib available for inhibition of Bcr-Abl (see Figure 1e) . 58 Both, the tumor burden in a mouse model 58 and the CML disease stage in humans, 59 correlated with plasma AGP levels, and a priori elevated plasma AGP levels led to a less rapid response to imatinib in human CML. 59 However, initially elevated plasma AGP levels were reversible in the course of treatment and did not affect the efficacy of the drug. 59 In addition, changes of imatinib plasma levels, indicating an effect of increased AGP levels on the distribution of imatinib, have not been found in relapsing patients in a phase I clinical trial. 19 Moreover, AGP purified from both normal and CML patients plasma failed to bind imatinib and did not abrogate inhibition of Ph+cells by imatinib in vitro. 60 In summary, the ability of AGP to bind and inhibit imatinib is a matter of debate, and the proof for AGP being a relevant mechanism of resistance in CML is still to be furnished.
Imatinib resistance in murine models of Bcr-Abl-induced leukemia
The establishment of a murine CML bone marrow retroviral transduction and transplantation model made it possible to investigate resistance to imatinib in mice. The CML-like myeloproliferative disorder in mice responds to treatment with imatinib with respect to hematologic response and prolongation of survival. 61, 62 Treatment with imatinib was in some cases associated with enhanced expression of BCR-ABL at the RNA and/or protein level, but there was no correlation with response. 61 In one study, seven out of nine mice relapsed with ALL after they initially responded to imatinib. 62 Secondary transplantation of resistant mice suggested that resistance to imatinib arose because of cell-intrinsic factors. 62 Sequencing of the BCR-ABL kinase domain revealed no mutations. 62 In vitro, imatinib still inhibited Bcr-Abl in resistant cells. Southern blot analysis of imatinib-treated mice showed a reduction in the number of viral integration sites, 61, 62 indicating clonal selection. Altogether, murine CML-like disease responds well to imatinib treatment but is not curable. The selection of clones that express Bcr-Abl at high levels may lead to resistant disease in some cases. However, clonal evolution seems to be the main mechanism of resistance towards imatinib in mice when a retroviral transduction and transplantation model is used.
Strategies to overcome or prevent resistance
The clinical activity of imatinib confirms the importance of the elevated Bcr-Abl tyrosine-kinase activity as the driving force in CML and Ph+ ALL. Resistance to the drug develops within short periods of time in advanced phase CML and Ph+ ALL. Recent observations also show mutations in relapsed accelerated and even in chronic phase CML. 41, 45, 47, 48 Moreover, mutated BCR-ABL has recently been tracked back to pre-treatment samples in chronic phase 45 and myeloid blast crisis CML, 47 indicating that imatinib selects for a pre-existing mutated clone that allows BcrAbl to be kinase-active in the presence of the drug. However, Bcr-Abl can still be considered as target for therapeutic intervention even in resistant disease. To prevent or overcome resistance, it will be crucial to use combinations of different inhibitors or molecular-based therapies together with conventional cytostatic agents. Principles learned from antibiotic resistance in infectious diseases may be applied to mutations conferring resistance to targeted therapy leading to a combination treatment as the standard of care. 63 In cases of mutations that confer partial resistance (Q252H, E355G, or H396P, see Table 1 ), increasing the imatinib dosage may result in a response even in the presence of the mutant clone.
Combination treatments with conventional antileukemic agents
In vitro data suggest additive and synergistic effects of imatinib in combination with antileukemic agents. [64] [65] [66] [67] A promising observation is an increase of the synergistic activity with chemotherapeutic agents such as cytarabine or etoposide at higher levels of growth inhibition by imatinib. 65, 67 Based on these findings, several clinical trials are investigating simultaneous or sequential regimens using imatinib together with established substances such as interferon and cytarabine (eg the German CML-study IV in chronic phase CML, CSTI571A-DE-01 in myeloid blast crisis CML, and GMALL-STI571-IFN in Ph+ ALL 53 Importantly and in contrast to imatinib, this substance demonstrated to bind Abl with the activation loop being in a conformation that resembles an activated kinase, and independent of its phosphorylation state. 53 Therefore, second-generation kinase inhibitors may be superior to imatinib with respect to the potency of Bcr-Abl inhibition. Apart from compounds that bind to the ATP-binding site, the transformation potential of Bcr-Abl may be specifically disrupted using compounds that bind to different domains in BcrAbl. Tyrphostins alter the binding of Bcr-Abl to substrates rather than blocking access to the ATP-binding site. Inhibition by tyrphostins lead to the degradation of Bcr-Abl and apoptosis of Bcr-Abl-positive cells. 68 Compounds acting on biologically relevant proteins other than Bcr-Abl are capable of specifically suppressing a Bcr-Abldependent phenotype. Inhibition of the molecular chaperone HSP90 with geldanamycin and its derivative 17-AAG induced Bcr-Abl degradation and apoptosis in cells expressing Bcr-Abl wild type, [69] [70] [71] and was active in cells expressing BCR-ABL mutants T315I and E255K. 72 Farnesyl protein transferase inhibitors (FTI) were specifically designed to block oncogenic Ras signaling through disruption of Ras prenylation, thereby preventing its translocation to the membrane. Inhibition of other farnesylated targets, including centromere-associated proteins, may be important for the activity of this class of compounds. 73, 74 In addition, the FTI SCH66336 was shown to inhibit the MDR-1 product Pgp, 75 which was overexpressed in the imatinibresistant cell line LAMA84-r. 31 SCH66336, apart from its activity in solid tumors, selectively inhibited Bcr-Abl expressing cell lines and primary human CML cells, 73 and was active in a murine model of Bcr-Abl-induced leukemia. 73, 76 In addition, SCH66336 inhibited the proliferation of imatinib-resistant cell lines and the colony formation of mononuclear cells derived from imatinib-resistant patients with amplification of BCR-ABL. 77 The coadministration of both drugs, imatinib and SCH66336, resulted in a synergistic increase in apoptosis in imatinib-sensitive cells. Furthermore, only the combination induced apoptosis in cells resistant to imatinib because of BCR-ABL amplification. 77 In contrast, there was no synergistic increase of apoptotic cells when Ba/F3 cells expressing the T315I mutant were exposed to both substances. 77 The authors concluded that a combination of both substances may be active in patients in whom imatinib resistance results from BCR-ABL amplification. A distinct FTI, R115777, proved to be active in patients with chronic phase CML. 78 Targeting BCR-ABL messenger RNA using antisense oligodeoxynucleotides (ODN) inhibited leukemia blast cells in vitro, 79 was effective in mice, 80 and has been utilized for in vitro purging. 81 However, problems of uptake, specificity, and toxicity limit the therapeutic use in patients. Small interfering RNAs (siRNA) may more specifically and efficiently interfere with the expression of BCR-ABL mRNA. 82 Moreover, since the structure of the Bcr-Abl oligomerization domain has been resolved, it may be possible to design inhibitors that specifically disrupt homodimerization and thus activation of Bcr-Abl. 83 Finally, an elegant approach has been generated recently by Vigneri and Wang: 84 entrapment of Bcr-Abl in the nucleus was achieved by treatment of cells with a combination of imatinib, promoting the nuclear import of cells, and leptomycin B (LMB), blocking its nuclear export. Bcr-Abl, trapped in the nucleus, recovered its activity after removal of imatinib. In the nucleus, active Bcr-Abl selectively induced apoptosis of CML cells. Importantly, as long as Bcr-Abl is expressed, this approach would work even in cases where the leukemic clone does not depend on Bcr-Abl any more because of secondary alterations that bypass its dependence on the oncogene. However, LMB displayed an unfavorable toxic profile in a phase I clinical trial in solid tumors. Profound anorexia and malaise were identified as dose-limiting toxicity. 85 Thus, the use of LMB may be limited to ex vivo applications such as purging bone marrow of CML cells. 84 In conclusion, combinations of imatinib and second-generation kinase inhibitors with established or novel antileukemic agents are about to be translated into clinical trials, and are expected not only to further improve the efficacy of current treatment options but also to prevent resistance by early eradication of all Ph-+ cells.
Discontinuation of imatinib
When mutant BCR-ABL is monitored, it must be kept in mind that wild-type disease may outgrow the mutated clone after cessation of imatinib therapy, as it has been described for Y253H. 48 Moreover, stopping imatinib may revert a BCR-ABLamplified phenotype, as demonstrated in a patient with blast crisis CML 36 and in vitro. 31, 34 In the imatinib-resistant cell line LAMA84-r, a decrease of Bcr-Abl protein and BCR-ABL gene copies, coinciding with restoration of sensitivity to imatinib, was observed upon removal of imatinib. 34 In addition, resistant cell lines that overexpressed Bcr-Abl showed a transient loss of viability and reduction of proliferation after withdrawal of imatinib, possibly caused by a sudden increase of kinase-active Bcr-Abl. 34 Thus, patients with imatinib resistance may respond again after an interval without imatinib.
Conclusions
Imatinib, a specific inhibitor targeting the deregulated tyrosine kinase Bcr-Abl, is capable of inducing impressive response rates as single agent in chronic phase CML, and also demonstrated significant activity in advanced phase CML and Ph+ ALL. However, there are doubts whether imatinib given as single agent can eradicate the malignant clone, since resistant disease clones frequently emerge in Ph+ ALL and blast crisis CML, and were detected even in single cases of chronic phase CML. The drug itself selects for clones that express Bcr-Abl at high levels or harbor secondary genetic alterations such as gene mutations within the kinase domain of BCR-ABL that prevent the drug from binding its target and result in a kinase-active oncoprotein in the presence of its inhibitor. A number of mutations that occur at positions predicted to be important for binding imatinib and that confer resistance to imatinib in vitro have now been identified. Good news, that mechanisms underlying resistance have been elucidated within a short period of time and that active Bcr-Abl in imatinib-resistant Ph+ leukemia is still the target of choice in a substantial proportion of cases. Future efforts should therefore focus on preventing resistant clones to emerge. Strategies that are currently tested in clinical trials include combination therapies of imatinib with synergistically acting conventional chemotherapeutic agents. Since imatinib selects for kinase domain mutations that specifically incapacitate imatinib but may not at the same time abrogate inhibition by alternate compounds, new small molecule inhibitors will be used to prevent and to overcome resistance. At the end, combination strategies will be used first line in order to completely eliminate leukemic cells as fast as possible, including putative pre-existing cells that contain mutated BCR-ABL.
